Lavipharm

Lavipharm Net Debt per Share

The Net Debt per Share of Lavipharm (LAVI.AT) as of Oct 31, 2026 is 0.13 EUR. In the previous year, Net Debt per Share was 0.17 EUR — a change of -21.14% (lower).

Net Debt per Share

0.13EUR

YoY

-21.14%

Last updated:

Net Debt per Share of Lavipharm is 2025 0.13 EUR. Net Debt per Share of Lavipharm was 2024 0.17 EUR. It decreases by -21.14% lower compared to the previous year.

The Lavipharm Net Debt per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt per Share
Date
Net Debt per Share
Jan 1, 2018
0.23 EUR
Jan 1, 2019
0.23 EUR
Jan 1, 2020
0.20 EUR
Jan 1, 2021
0.21 EUR
Jan 1, 2022
0.11 EUR
Jan 1, 2023
0.14 EUR
Jan 1, 2024
0.17 EUR
Jan 1, 2025
0.13 EUR
The Lavipharm Net Debt per Share history
YEARNet Debt per ShareYoY
0.13EUR-21.14%
0.17EUR+17.93%
0.14EUR+27.15%
0.11EUR-47.26%
0.21EUR+3.97%
0.20EUR-11.93%
0.23EUR+0.72%
0.23EUR-1.10%
0.23EUR-49.43%
0.46EUR-5.46%
0.49EUR+32.04%
0.37EUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lavipharm Stock analysis

What does Lavipharm do? Lavipharm SA manufactures and imports pharmaceuticals and veterinary products, with main categories including anti-inflammatory, asthma controlling, neurological, antiseptic, analgesic, dermatological, and gastrointestinal therapies. The company offers cosmetic products under the brands Castalia Soins Dermocosmetiques and Laviderm Active Technology for skin, face, body, scalp, and hair care. Its OTC products encompass cold and flu remedies, oral care, dermatological items, condoms, antiseptics, analgesics, laxatives, and gynecology products. The company is the parent of Lavipharm Group of Companies and previously sold HITEX, a carbon dioxide extraction subcontracting business, to Robertet SA and CODIF in January 2014. Lavipharm SA's revenue streams come from the sale of pharmaceuticals, veterinary products, cosmetics under Castalia and Laviderm, and OTC products. Pharmaceutical and veterinary products target healthcare providers and pharmacies, while cosmetics and OTC products are sold directly to consumers through retail channels. The company's brand portfolio includes Castalia Soins Dermocosmetiques, Laviderm Active Technology, and its core pharmaceutical lines, with segments defined by product categories and distribution channels. The company's primary customers are healthcare professionals and retail consumers, with pharmaceuticals distributed via pharmacies and veterinary products to animal care facilities. Cosmetic products under Castalia and Laviderm are sold to consumers for personal care, and OTC products reach consumers through general retail. The sale of HITEX to Robertet SA and CODIF in 2014 was a one-time transaction that contributed to the company's financials during that period. Lavipharm is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lavipharm stock

Net Debt per Share of Lavipharm is 0.13 EUR in 2025.

Net Debt per Share of Lavipharm changed from 0.17 EUR to 0.13 EUR, representing a -21.14% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt per Share Lavipharm since 2006 – with annual values, charts, and detailed analysis.

Net debt per share divides net debt by shares outstanding, showing the debt burden attributable to each share after accounting for cash reserves.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — Lavipharm

All Key Metrics — Lavipharm